Идёт набор NCT06814925

Italian Study of Patients With Lymphoma

— Наблюдательное Lymphoma

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально: Состояния в реестре: Lymphoma. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Италия
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Italian Prospective Observational Cohort Study of Patients With Lymphoma

Обзор

It is an observational, non-interventional, prospective, monocentric study, whose objective is to enroll 1500 patients with lymphoma in 5 years within the Institute of Hematology "Seragnoli".

Подробное описание

The study is aimed at enriching the data on the prognostic role of genetic and epidemiological factors associated with clinical and epidemiological data of patients; to identify factors that influence the evolution of the disease, such as lifestyle and occupational factors, as well as the type of treatment; to document the impact of the disease on quality of life and to provide a platform for future research projects.

Study-specific questionnaires will be administered to patients, both at baseline and during follow-up, which methodologically represent a useful tool in order to achieve these objectives.

Первичные конечные точки

Overall Survival (OS) [Срок оценки: through study completion, an average of 5 years]

Вторичные конечные точки (12)

Event Free Survival (EFS) [Срок оценки: through study completion, an average of 5 years]
Lymphoma Specific Survival (LSS) [Срок оценки: through study completion, an average of 5 years]
Progression-Free Survival (PFS) [Срок оценки: through study completion, an average of 5 years]
net survival [Срок оценки: through study completion, an average of 5 years]
response rate [Срок оценки: through study completion, an average of 5 years]
Duration of response [Срок оценки: through study completion, an average of 5 years]
Time to next anti-lymphoma treatment (TTNLT) [Срок оценки: through study completion, an average of 5 years]
Duration of survival after progression [Срок оценки: through study completion, an average of 5 years]
Frequency of lymphoma transformation [Срок оценки: through study completion, an average of 5 years]
Frequency of secondary cancers [Срок оценки: through study completion, an average of 5 years]
Frequency of other chronic diseases [Срок оценки: through study completion, an average of 5 years]
questionnarire of Quality of Life FACT-LYM (Functional Assessment of Cancer Therapy-Lymphoma): score 0 to 4 [Срок оценки: through study completion, an average of 5 years]

Критерии участия

Критерии включения

Age greater than or equal to 18 years at enrollment
Diagnosis of lymphoma within 3 months of enrollment
Patients may have been treated, as long as the initial diagnosis of lymphoma is within 3 months of enrollment
Signing of the informed consent form